Issue 32

Faster, Leaner, More Efficient: The Future of Biomanufacturing

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

How CDMOs Are Driving the Adoption of Continuous Biomanufacturing

Biopharma companies are increasingly dependent on CDMOs to streamline production, enhance efficiency, and accelerate drug development. As therapies become more complex and regulatory demands grow, the ability to outsource manufacturing to a trusted partner has never been more essential.

Read more here.

FEATURED STORIES

Terumo’s Ultimaster™ Stents Gain MDR Approval for High-Bleeding Risk Patients

Read more here.

Aenova Expands Production with USD 22 Million Investment

Read more here.

Almac Group's £65M Investment in Northern Ireland Manufacturing Facility

Read more here.

Axplora Enhances ADC Manufacturing at Le Mans Facility

Read more here.

GBI Appoints Industry Veteran Sven Lee to Board of Directors

Reda more here.

Asimov and Lotte Biologics Collaborate to Accelerate GMP Manufacturing

Read more here.

CordenPharma and Viking Forge Partnership for GLP-1 Drug Candidate VK2735

Read more here.

Syngene Opens First U.S. Manufacturing Facility to Expand CDMO Services

Reda more here.

Vetter Completes Third Expansion Phase of Visual Inspection and Logistics Center

Read more here.

ENCell Partners with Cell Resources and Secures CDMO Contract with CELLeBRAIN

Read more here.

Humanetics Partners with Lifecore Biomedical to Advance BIO 300 for Acute Radiation Syndrome Prevention

Read more here.

Adragos Significantly Increases Japanese Capacity

Read more here.

Shilpa Medicare Unveils Hybrid CDMO Model at DCAT 2025

Read more here.